Page last updated: 2024-11-05

2-methylquinoxaline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Methylquinoxaline is a heterocyclic compound that has been studied for its potential applications in various fields, including medicine and materials science. It is a derivative of quinoxaline, a nitrogen-containing heterocyclic compound known for its biological activity.

The synthesis of 2-methylquinoxaline typically involves the condensation reaction of o-phenylenediamine with a suitable carbonyl compound, such as pyruvate or acetoin. The reaction proceeds under acidic conditions and yields the desired product.

2-Methylquinoxaline has been investigated for its pharmacological properties. It has shown promising activity as an anticancer agent, exhibiting cytotoxicity against certain cancer cell lines. Additionally, it has been explored as a potential antibacterial agent, displaying activity against gram-positive bacteria.

The unique electronic and structural properties of 2-methylquinoxaline have led to its exploration in the field of materials science. It has been incorporated into organic light-emitting diodes (OLEDs) as an emissive material, contributing to the development of efficient and bright displays.

Further research into 2-methylquinoxaline is driven by its potential as a building block for new and improved pharmaceuticals, materials, and other applications. The compound's versatility and biological activity make it a promising candidate for further investigation and development.'

2-methylquinoxaline: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-methylquinoxaline : A quinoxaline derivative in which the quinoxaline (1,4-naphthyridine) skeleton is substituted at C-2 with a methyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID23686
CHEMBL ID3287983
CHEBI ID132812
SCHEMBL ID28571
MeSH IDM0148525

Synonyms (40)

Synonym
ccris 2948
nsc 65587
ai3-50958
brn 0113307
einecs 230-664-9
AKOS015842561
NCIOPEN2_000305
inchi=1/c9h8n2/c1-7-6-10-8-4-2-3-5-9(8)11-7/h2-6h,1h
7251-61-8
nsc65587
2-methylquinoxaline
quinoxaline, 2-methyl-
nsc-65587
2-methylquinoxaline, 97%
2-methylquinoxaline, >=97%
2-methyl-1,4-naphthyridine
CHEBI:132812
M0580
A9429
03vu31mv6j ,
unii-03vu31mv6j
5-23-07-00219 (beilstein handbook reference)
FT-0613078
CHEMBL3287983
2-methyl-quinoxaline
2-methyl quinoxaline
methyl-quinoxaline
SCHEMBL28571
DTXSID50222831
W-104484
STL451646
mfcd00006727
AMY36538
Q27225675
AS-57153
2-methyl chinoxaline
CS-W016388
EN300-120446
SY031444
Z1255423472
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinoxaline derivativeAny naphthyridine derivative that is a derivative of quinoxaline (1,4-naphthyridine).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1859299Inhibition of palmitate-induced lipid accumulation in human HepG2 cells relative to control2022European journal of medicinal chemistry, Feb-05, Volume: 229Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
AID1156429Antiplasmodial activity against chloroquine-, pyrimethamine- and proguanil-resistant Plasmodium falciparum K1 infected in human erythrocytes after 72 hrs by SYBR Green I fluorescence-based method2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and in vitro evaluation of 4-trichloromethylpyrrolo[1,2-a]quinoxalines as new antiplasmodial agents.
AID1156430Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Synthesis and in vitro evaluation of 4-trichloromethylpyrrolo[1,2-a]quinoxalines as new antiplasmodial agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (28.57)18.7374
1990's2 (28.57)18.2507
2000's1 (14.29)29.6817
2010's1 (14.29)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.76 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index25.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]